<DOC>
	<DOC>NCT02991599</DOC>
	<brief_summary>This is a randomized, controlled trial. The study will evaluate the immunogenicity, immune persistence, and safety of 20 µg and 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6 in methadone maintenance treatment patients.</brief_summary>
	<brief_title>Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Aged between 18 and 70 years at the enrolment Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (antiHBs) at enrollment Willing to adhere to the study protocol Being pregnant Intolerance or allergy to any component of the vaccine Any vaccination during the month preceding enrollment Ongoing opportunistic infection Liver disease Hematological disorder Cancer Unexplained fever the week before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B, Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>methadone maintenance treatment</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>